Literature DB >> 7143333

Partial ileal bypass in treatment of familial hypercholesterolaemia.

L J Chalstrey, A F Winder, D J Galton.   

Abstract

The effects of partial ileal bypass have been studied in 7 patients with heterozygous familial hypercholesterolaemia. By the seventh to ninth postoperative day there was a significant fall in plasma cholesterol of 42.8% compared with levels at initial presentation. Thereafter, plasma levels of cholesterol rose by varying degrees, but had stabilized by 3 months with average values 29.5% lower than pretreatment. Debilitating diarrhoea or severe weight loss were not troublesome features of the operation in most patients.

Entities:  

Mesh:

Year:  1982        PMID: 7143333      PMCID: PMC1438421          DOI: 10.1177/014107688207501105

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  5 in total

1.  Cholestyramine and ileal by-pass in the treatment of familial hypercholesterolaemia.

Authors:  T A Miettinen; M Lempinen
Journal:  Eur J Clin Invest       Date:  1977-12       Impact factor: 4.686

2.  Simultaneous measurement of apolipoprotein B turnover in very-low-and low-density lipoproteins in familial hypercholesterolaemia.

Authors:  A K Soutar; N B Myant; G R Thompson
Journal:  Atherosclerosis       Date:  1977-11       Impact factor: 5.162

3.  Treatment of familial hypercholesterolaemia by partial ileal bypass.

Authors:  D Russell; V Fritz; C J Mieny; D Mendelsohn; B I Joffe; H C Seftel
Journal:  S Afr Med J       Date:  1979-02-17

4.  Superiority of partial ileal bypass over cholestyramine reducing cholesterol in familial hypercholesterolaemia.

Authors:  F A Spengel; A Jadhav; R G Duffield; C B Wood; G R Thompson
Journal:  Lancet       Date:  1981-10-10       Impact factor: 79.321

5.  Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia.

Authors:  D R Illingworth; B E Phillipson; J H Rapp; W E Connor
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.